drugset / Trial / NCT07389174
Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a single-centre, randomised, paired 24-week intervention dosing trial. Its purpose is to evaluate the safety profile and efficacy of the investigational drug in subjects with metastatic hormone-sensitive prostate cancer receiving oral LC-K76 treatment. Following a screening period not exceeding three weeks, subjects will enter a one- to two-week matching and randomization phase. Subsequently, subjects will be assigned to receive the study drug for a 24-week treatment period, followed by a 24-week follow-up period.
Timeline
- Start
- 2026-02
- Primary completion
- 2027-01
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LC-K76 | Unknown | 1.2 g | Oral |
| Background | Abiraterone acetate | Small molecule | — | Oral |
| Background | Apalutamide | Small molecule | — | Oral |
| Background | Darolutamide | Other / unclassified | — | Oral |
| Background | Degarelix | Other / unclassified | — | — |
| Background | Enzalutamide | Other / unclassified | — | Oral |
| Background | Goserelin | Other / unclassified | — | — |
| Background | Leuprolide | Other / unclassified | — | — |
| Background | Rezvilutamide | Small molecule | — | Oral |
| Background | Triptorelin | Other / unclassified | — | — |